

Fig. S1. PDGFRα, but not PDGFRβ, is required for trimer-only HCMV infection. (A) HFF cells were transduced with lentiviruses expressing Cas9 and non-targeting gRNAs, or gRNAs specific for PDGFRa or PDGFRb. 14 days after transduction, cell surface staining of PDGFRa and PDGFRB was measured prior to sorting by FACS. (B) PDGFRa-low or PDGFRβ-low populations were sorted by FACS from HFF cells expressing gRNAs against PDGFRα or PDGFRβ as shown above, and surface staining was performed to confirm the purity of sorted cells. (C) PDGFRα-low, PDGFRβ-low and control cells were infected by AD169-GFP or Merlin-GFP (pAL1158) at multiplicity of 3 FFU/cell, and GFP expressed from the viral genome was monitored by flow cytometry to determine the percentage of infected cells at 1 dpi. (D) AD169-GFP and Merlin-GFP yields from cells infected in panel C were quantified at 5 dpi. Mean ± SD is presented for three biological replicates assayed in triplicate.



**Fig. S2. EGFR and HER2 are not required for AD169 derivatives containing the pentameric complex to enter PDGFRα-KO fibroblasts or ARPE-19 epithelial cells.** PDGFRα-KO cells (clone 1-10) (A) and ARPE-19 cells (B) were transduced with lentiviruses expressing shRNAs targeting EGFR, HER2 or both. Top panels: Cell surface staining of EGFR and HER2 was performed to confirm the knockdown. Bottom panels: Cells were infected with AD169*r*UL131A-GFP-epi at a multiplicity of 3 FFU/cell, and GFP expression was measured at 24 hpi to assay the percentage of infected cells. The percentage of IE1-positive cells is labeled in red. Control: cells without lentiviral transduction; shNT: non-targeting shRNA.



**Fig. S3. EGFR and HER2 are not required for TB40/E to enter ARPE-19 epithelial cells.** ARPE-19 cells were transduced with lentiviruses expressing shRNAs targeting both EGFR and HER2. shRNAs labeled #1 correspond to those used in the experiment reported in figure S2, and shRNAs labeled #2 correspond to the additional set. Top panels: Cell surface staining of EGFR and HER2 was performed to confirm the knockdown. Bottom panels: Cells were infected with AD169*r*UL131A-GFP-epi or TB40/E-epi at a multiplicity of 3 FFU/cell, and IE1 expression was measured at 24 hpi to assay the percentage of infected cells. The percentage of IE1-positive cells is labeled in red. Control: ARPE-19 cells without lentiviral transduction; shNT: nontargeting shRNA.





Fig. S4. IgG-like domain 3, but not the kinase domain, is required for trimer-only HCMV to enter PDGFRaexpressing ARPE-19 cells. (A) ARPE-19 cells were transduced with lentiviruses expressing V5-tagged, full-length or deleted variants of PDGFRa. Transduced ARPE-19 cells were infected with AD169-GFP at a multiplicity of 3 FFU/cell, and GFP-positive cells were quantified at 24 hpi by flow cytometry. (B) Expression of V5-tagged full length and truncated PDGFRa variants in ARPE-19 was confirmed by western blot. M: protein marker. (C) Transduced ARPE-19 cells were infected with AD169-fibro, Merlin-fibro (pAL1111) or TB40/E-fibro at a multiplicity of 3 FFU/cell, and IE1-positive cells were quantified at 24 hpi by flow cytometry. (D) Viral genomes were quantified in cells infected in (C) at 4 dpi by qPCR using primers specific for the viral UL44 coding region and the cellular GAPDH locus. Mean  $\pm$  SD is presented for three biological replicates assayed in triplicate.

(pAL1111)



Fig. S5. Entry of trimer-only virus into PDGFRa-expressing ARPE-19 cells is pH independent. ARPE-19 cells transduced with lentivirus expressing PDGFRa or empty vector were pre-treated with 40 nM bafilomycin A1 (BFA) (A) or 40  $\mu$ M NH4Cl (B) for 1 h prior to infection with TB40/E-fibro, Merlinfibro, or AD169-fibro at a multiplicity of 3 FFU/cell in the presence of the inhibitor for 1 h at 37°C. Infected cells were cultured with inhibitors and IE1 expression was assayed at 20 hpi to measure the percentage of infected cells. The percentage of IE1-positive cells is labeled in red.

CLUSTAL O(1.2.4) multiple sequence alignment AA91-130 0 D3-AA202-306 PFNVYALKATSELDLEMEALKTVYKSGETIVVTCAVFNNEVVDLQWTYPGEVKGKGITML 60 AA91-130 -----SAAHTGLYTCYYNHTQTEENELEGRHIYIYVPDPDVAFVP 40 D3-AA202-306 EEIKVPSIKLVYTLTVPEATVKDSGDYECAARQATREVKEMKKVT----- 105 :. .:\* \* \* .:: \* :\*:

Fig. S6. Amino acid sequence alignment between PDGFRα amino acid 91-130 and IgG-like domain 3 (amino acid 202-306).

## Table S1

GeCKO-1st PCR primer	Sequence					
v2Adaptor_F	AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG					
v2Adaptor_R	TCTACTATTCTTTCCCCTGCACTGTtgtgggcgatgtgcgctctg					
GeCKO-2nd PCR Primer	Illuming flowcell attachment sequence & Illuming sequencing primer sequence	Barcode	Priming cite	Longth	Purification	Complete Drimer Sequence
F01		CGATGT	tettatagaaagacgaaacacacg	20	PAGE	
F02		TGACCA	tettataaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	00	PAGE	
F02		ACAGTG	tettataaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	00	PAGE	
F03		GCCAAT	tettataaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	00	PAGE	ANTO A TAC GOLGA CONCACTOR AND A CONCENTRATION OF A CONCENTRATIONO OF A CONCENTRATICA CONCENTRATICA CONCENTRATICA CONCENTRATICO
F04		GCCAAT	tettataaaaagacgaaacaccg	00	PAGE	A ATCA TA COCCA COLACIDA CATCITACA COLORICA COLORICA COLATORIA CALLER STREAM AND A STATISTICA COLACIDATION COLACIDATICA COLACIDATICACIDA COLACIDATICA COLACIDATICA COLACIDATICA COLACIDATIC
FUS		CAGATC	tettatage og gangadaddug	00	PAGE	
F08		ATCACC	tettatage og gangadaddug	00	PAGE	AATOATACGGCGACCACCGACGACGACGACGTCTTTCCCTACACCGACGCTCTTCCCATCTCTTGTACLLIgtggdadggddggddddtg
F07		TACCC	tettatage og gangadaddug	00	PAGE	AATOATACGGCGACCACCGACGACTCTACACTCTTTTCCCTACGACCGAC
F00		ACTTCA	tettataaaaagacgaaacaccg	00	PAGE	
F09		GATCAG	tettatagaaaggacgaaacaccg	00	PAGE	
F10		TAGCTT	tettataaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa	00	PAGE	ANTO A TAC GOLGA CONCACTOR AND A CONCENTRATION OF A CONCENTRATICA CONCENTRATICA CONCENTRATICA CONCENTRATICA CONCENTRATICA CONCENTRATICA CONCENTRAT
F11		CCCTAC	tettataaaaagacgaaacaccg	00	PAGE	
R01	CAAGCAGAAGACGGCATACGAGAT	GGCTAC	TCTACTATTCTTTCCCCTGCACTGT	49	PAGE	CAAGCAGAAGACGGCATACGAGATTCTACACTCTTTCCCCTACACGCTCTTCCGCATCTGGCTACtCttgtggaaaggadgaaggadgaadacactg
Primer Name	Primer Sequence ( <u>gRNA</u> )	Source				
PDGFRa_gRNA_1_Fwd		GeckOv2 library				
PDGFRa_gRNA_1_Rev	AAACGGGTAAGTCCATTGAAGGTCC					
PDGFRa_gRNA_8_Fwd	CALLGLIAAGALLAGGAALGLLGGA	Designed by Desktop Genetics				
PDGFRa_gRNA_8_Rev	AAAC <u>TCCGGCGTTCCTGGTCTTAG</u> C					
PDGFRa_gRNA_10_Fwd	CACCGCGTTTCCCCTGACTTATACA	Designed by Desktop Genetics				
PDGFRa_gRNA_10_Rev		Dealers of the Dealeters Constitution				
PDGFRD_gRNA_11_FW0		Designed by Desktop Genetics				
PDGFRD_gRNA_11_Rev		GoCKOv2 library				
non-targeting_gRNA_Fwu		Geckovz library				
non-targeting gRNA_Rev		GeCKOv2 library				
non-targeting gRNA 2 Rev		Geekovz library				
non targeting_Bitter_2_iter					Note for De	letion Variant
PDGFRa gRNA1 Q5 Fwd	ggacctatccTGGAGAAGTGAAAGGCAAAG					
PDGFRa gRNA1 Q5 Rev	actgcaaatcAACCACCTCATTGTTAAAAAC					
Ra-FL-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGG					
Ra-SP-115-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAG	GGCTGAGCCTAATCCTCTGCAGGCAG	CATTTACATCTATGTGCCAGAC		ΔD1 (ΔΑΑ24	-114)
Ra-SP-202-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAG	GGCTGAGCCTAATCCTCTGCCCATTT	AATGTTTATGCTTTAAAAGCAACATCA	١G	ΔD1D2 (ΔΑΑ	224-201)
Ra-SP-319-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAG	GGCTGAGCCTAATCCTCTGCCCCACC	TTCAGCCAGTTGGA		ΔD1-D3 (ΔΑ	A24-318)
Ra-SP-414-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAG	GGCTGAGCCTAATCCTCTGCCCTTCA	TCCATTCTGGACTTGGTC		ΔD1-D4 (ΔΑ	A24-413)
Ra-SP-520-V5 Fwd	attcgcGGATCCACCATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAG	GGCTGAGCCTAATCCTCTGCACCCTG	CGTTCTGAACTCACG		ΔD1-D5 (ΔΑ	A24-519)
Ra-1-592-V5 Rev	atcgtaACGCGTCGTAGAATCGAGACCGAGGAGAGGGGTTAGGGATAGGCTTACCGCCACCTC	CATCTCTTGGAAACTCCCATCTTG			ΔC (ΔΑΑ593-	-1089)
Ra-FL-V5-STOP Rev	atcgtaACGCGTTTACGTAGAATCGAGAACCGAGGAGAGGGGTTAGGGATAGGCTTACCGCCACCCAGGAAGCTGTCTTCCACCAGG				- •	
Ra-FL_Rev	atcgtaACGCGTTTACAGGAAGCTGTCTTCCACCAGG					
		Adapted from Sigma Mission sh	RNA:			
shNT Fwd	CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTG	SHC002				
shNT Rev	AATTCAAAAACAACAAGATGAAGAGGAGCACCAACTCGAGTTGGTGGTGCTCTCATCTTGTG					
shEGER 1 Ewd	CCGGGCCACAAAGCAGTGAATTTATCTCGAGATAAATTCACTGCTTTGTGGCTTTTTG	TRCN0000295969				
shEGFR 1 Rev	AATTCAAAAAGCCACAAAGCAGTGAATTTATCTCGAGATAAATTCACTGCTTTGTGGC					
shEGFR 2 Fwd	CCGGGCTGGATGATAGACGCAGATACTCGAGTATCTGCGTCTATCATCCAGCTTTTTG	TRCN0000298822				
shEGFR_2_Rev	AATTCAAAAAGCTGGATGATAGACGCAGATACTCGAGTATCTGCGTCTATCATCCAGC					
shHER2_1_Fwd	CCGGTGTCAGTATCCAGGCTTTGTACTCGAGTACAAAGCCTGGATACTGACATTTTTG	TRCN0000039878				
shHER2_1_Rev	AATTCAAAAATGTCAGTATCCAGGCTTTGTACTCGAGTACAAAGCCTGGATACTGACA					
shHER2_2_Fwd	CCGGGAATATGTGAACCAGCCAGATCTCGAGATCTGGCTGG	TRCN0000039882				
shHER2_2_Rev	AATTCAAAAAGAATATGTGAACCAGCCAGATCTCGAGATCTGGCTGG					
UL44_F	GTGCGCGCCCGATTTCAATATG	for qPCR				
UL44_R	GCTTTCGCGCACAATGTCTTGG	for qPCR				
gGAPDH_F	CCCCACACATGCACTTACC	for qPCR				
gGAPDH_R	CCTAGTCCCAGGGCTTTGATT	for qPCR				